Shots:
- The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025
- Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBO
- Mometamax Single is a single-dose in-clinic treatment for otitis externa in dogs caused by susceptible strains of Malassezia pachydermatis, Staphylococcus pseudintermedius & Pseudomonas aeruginosa
Ref: Merck Animal Health | Image: Merck Animal Health
Related News:- Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for the Full Press Release
